BioLife Solutions, Inc. (NASDAQ:BLFS) CMO Sells $10,795.04 in Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) CMO Todd Berard sold 424 shares of BioLife Solutions stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $25.46, for a total value of $10,795.04. Following the sale, the chief marketing officer now directly owns 106,538 shares in the company, valued at $2,712,457.48. The trade was a 0.40 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.

Todd Berard also recently made the following trade(s):

• On Wednesday, February 12th, Todd Berard sold 102 shares of BioLife Solutions stock. The shares were sold at an average price of $26.54, for a total value of $2,707.08.
• On Monday, January 6th, Todd Berard sold 343 shares of BioLife Solutions stock. The stock was sold at an average price of $27.02, for a total transaction of $9,267.86.

BioLife Solutions Stock Up 5.7 %

Shares of NASDAQ:BLFS traded up $1.41 on Wednesday, reaching $26.25. The company had a trading volume of 502,346 shares, compared to its average volume of 270,046. BioLife Solutions, Inc. has a 52-week low of $14.84 and a 52-week high of $29.55. The firm’s 50 day simple moving average is $26.67 and its 200-day simple moving average is $25.48. The company has a current ratio of 2.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.03. The firm has a market capitalization of $1.22 billion, a PE ratio of -24.76 and a beta of 1.91.

BioLife Solutions (NASDAQ:BLFS) last announced its earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.32. BioLife Solutions had a negative return on equity of 6.61% and a negative net margin of 38.98%. The business had revenue of $22.71 million during the quarter, compared to the consensus estimate of $21.73 million. During the same period in the prior year, the company posted ($0.21) EPS. As a group, analysts expect that BioLife Solutions, Inc. will post -0.3 earnings per share for the current fiscal year.

Institutional Trading of BioLife Solutions

Several institutional investors have recently added to or reduced their stakes in the stock. D.A. Davidson & CO. boosted its stake in BioLife Solutions by 1.3% in the fourth quarter. D.A. Davidson & CO. now owns 41,179 shares of the medical equipment provider’s stock valued at $1,069,000 after acquiring an additional 519 shares in the last quarter. Stifel Financial Corp increased its stake in shares of BioLife Solutions by 5.4% during the 3rd quarter. Stifel Financial Corp now owns 12,988 shares of the medical equipment provider’s stock valued at $325,000 after acquiring an additional 670 shares during the last quarter. 1620 Investment Advisors Inc. increased its position in shares of BioLife Solutions by 41.7% in the fourth quarter. 1620 Investment Advisors Inc. now owns 2,295 shares of the medical equipment provider’s stock worth $60,000 after acquiring an additional 675 shares in the last quarter. Smartleaf Asset Management LLC grew its holdings in BioLife Solutions by 27.0% during the 4th quarter. Smartleaf Asset Management LLC now owns 4,469 shares of the medical equipment provider’s stock valued at $117,000 after purchasing an additional 950 shares in the last quarter. Finally, Steward Partners Investment Advisory LLC bought a new position in BioLife Solutions during the 4th quarter worth approximately $26,000. Institutional investors and hedge funds own 93.24% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Benchmark reiterated a “buy” rating and issued a $30.00 price target on shares of BioLife Solutions in a research report on Thursday, December 19th. Craig Hallum raised their price target on shares of BioLife Solutions from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. TD Cowen increased their target price on shares of BioLife Solutions from $28.00 to $31.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. HC Wainwright decreased their target price on shares of BioLife Solutions from $29.00 to $27.00 and set a “buy” rating for the company in a research report on Monday, November 18th. Finally, Northland Securities lifted their price target on shares of BioLife Solutions from $28.00 to $31.00 and gave the company an “outperform” rating in a research note on Wednesday, January 8th. One investment analyst has rated the stock with a sell rating and seven have issued a buy rating to the stock. According to MarketBeat.com, BioLife Solutions has a consensus rating of “Moderate Buy” and a consensus target price of $29.43.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.